TEVA Stock Overview
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TEVA from our risk checks.
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.03 |
| 52 Week High | US$11.45 |
| 52 Week Low | US$7.09 |
| Beta | 1.17 |
| 1 Month Change | 11.57% |
| 3 Month Change | 4.92% |
| 1 Year Change | 16.36% |
| 3 Year Change | -0.30% |
| 5 Year Change | -45.61% |
| Change since IPO | 1,237.33% |
Recent News & Updates
Recent updates
Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 203 Reasons To Buy Teva At $10
Apr 07Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24Teva Pharmaceutical: Prepare For Takeoff
Feb 16Teva: Competent Management Despite Lawsuits And Debts
Jan 28Teva: Bracing For Next Catalyst
Dec 22Teva: Definitely Undervalued
Dec 12Teva Pharmaceutical Industries (NYSE:TEVA) Seems To Be Using A Lot Of Debt
Dec 07Five Considerations After Teva Pharmaceuticals' Q3 Report
Oct 31Teva: Cautiously Bullish On 5-Year Prospects
Sep 17The Possible Reason why Teva (NYSE:TEVA) is Still Trading Below Intrinsic Value
Sep 17Why Teva Pharmaceuticals Has Two A-Products In The Bag
Aug 10Shareholder Returns
| TEVA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.5% | 1.6% | 0.9% |
| 1Y | 16.4% | -3.0% | 13.6% |
Return vs Industry: TEVA exceeded the US Pharmaceuticals industry which returned -3% over the past year.
Return vs Market: TEVA exceeded the US Market which returned 13.6% over the past year.
Price Volatility
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TEVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: TEVA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 34,565 | Richard Francis | https://www.tevapharm.com |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| TEVA fundamental statistics | |
|---|---|
| Market Cap | US$10.88b |
| Earnings (TTM) | -US$2.21b |
| Revenue (TTM) | US$15.27b |
0.7x
P/S Ratio-5.1x
P/E RatioIs TEVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEVA income statement (TTM) | |
|---|---|
| Revenue | US$15.27b |
| Cost of Revenue | US$8.27b |
| Gross Profit | US$7.00b |
| Other Expenses | US$9.21b |
| Earnings | -US$2.21b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 45.84% |
| Net Profit Margin | -14.46% |
| Debt/Equity Ratio | 265.9% |
How did TEVA perform over the long term?
See historical performance and comparison